Legal & General Group
AMAM

Legal & General Group’s Ambrx Biopharma Inc AMAM Stock Holding History

Legal & General Group’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,381
Closed -$15.9K – 3389
2023
Q3 		$15.9K Buy
+1,381
New +$18.8K ﹤0.01% 3118

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Legal & General Group's AMAM Position: Q4 2023 in Review

Legal & General Group sold out of Ambrx Biopharma Inc (AMAM) in Q4 2023, closing a stake of 1,381 shares — an estimated $15.9K sold.

Legal & General Group first reported a position in AMAM in Q3 2023 and held it in 1 quarter. The position peaked at $15.9K in Q3 2023. 68 funds tracked by Wall St. Rank hold AMAM as of Q4 2023.

  • Legal & General Group reported no remaining Ambrx Biopharma Inc position as of Q4 2023 after selling out during the quarter.
  • Legal & General Group sold 1,381 Ambrx Biopharma Inc shares in Q4 2023, an estimated $15.9K.
  • Legal & General Group first reported a position in Ambrx Biopharma Inc in Q3 2023 and held it in 1 quarter.
  • Legal & General Group's Ambrx Biopharma Inc position peaked at $15.9K in Q3 2023.
  • 68 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q4 2023.

Based on Legal & General Group's 13F filing for Q4 2023, filed 15 Feb 2024.